Core Insights - Catheter Precision, Inc. has secured its first multi-year agreement in France for the VIVO™ system, marking a significant commitment to the French electrophysiology market [1][4] - The VIVO system will be installed at the Centre Hospitalier Régional Universitaire (CHRU) Nancy, enhancing the hospital's capabilities in complex arrhythmia ablation [1][2] - This follows a successful deployment at CHU Rennes, which was Catheter Precision's largest purchase order in Europe, indicating strong demand and positive early results [3][4] Company Overview - Catheter Precision is a US-based medical device company focused on developing advanced technologies for cardiac electrophysiology [6] - The company aims to improve treatment for cardiac arrhythmias through innovative solutions and collaboration with healthcare professionals [6] Product Details - The VIVO system is a non-invasive 3D imaging technology that helps physicians identify the origins of ventricular arrhythmias before procedures, thereby streamlining workflows and reducing procedure times [5] - VIVO has received marketing clearance from both the U.S. FDA and has the CE Mark, indicating its compliance with regulatory standards [5] Market Position - The installation of VIVO at prestigious hospitals like CHRU Nancy and CHU Rennes reflects the growing momentum and clinical value of the product in the French market [4] - The involvement of leading academic centers is crucial for the early adoption of VIVO among physicians, which is expected to drive long-term usage [4]
Catheter Precision Announces Third VIVO Installation in France